239 related articles for article (PubMed ID: 16939487)
1. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
Appelbaum FR; Kopecky KJ; Tallman MS; Slovak ML; Gundacker HM; Kim HT; Dewald GW; Kantarjian HM; Pierce SR; Estey EH
Br J Haematol; 2006 Oct; 135(2):165-73. PubMed ID: 16939487
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
5. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
6. [Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation].
Shi HX; Jiang B; Qiu JY; Lu XJ; Fu JF; Wang DB; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):481-4. PubMed ID: 16383240
[TBL] [Abstract][Full Text] [Related]
7. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Schlenk RF; Benner A; Krauter J; Büchner T; Sauerland C; Ehninger G; Schaich M; Mohr B; Niederwieser D; Krahl R; Pasold R; Döhner K; Ganser A; Döhner H; Heil G
J Clin Oncol; 2004 Sep; 22(18):3741-50. PubMed ID: 15289486
[TBL] [Abstract][Full Text] [Related]
8. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic significance of cytogenetic changes in patients with acute myeloid leukemia (AML). (Analysis of results in 105 patients treated at the Hemato-oncology Clinic of the University Hospital in Olomouc from 1997 to 2000].
Jarosová M; Indrák K; Holzerová M; Hubácek J; Faber E; Papajík T; Raida L; Szotkowski T; Knotková R; Hlusí T; Jedlicková K; Pikalová Z; Sulovská I
Vnitr Lek; 2001 Sep; 47 Suppl 1():8-14. PubMed ID: 11693065
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
Larson RA; Le Beau MM
Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
[TBL] [Abstract][Full Text] [Related]
12. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
13. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Byrd JC; Ruppert AS; Mrózek K; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Stamberg J; Koduru PR; Moore JO; Mayer RJ; Davey FR; Larson RA; Bloomfield CD
J Clin Oncol; 2004 Mar; 22(6):1087-94. PubMed ID: 15020610
[TBL] [Abstract][Full Text] [Related]
14. Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience.
Lee KW; Choi IS; Roh EY; Kim DY; Yun T; Lee DS; Yoon SS; Park S; Kim BK; Kim NK
Ann Hematol; 2004 Apr; 83(4):218-24. PubMed ID: 14628154
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
17. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Giles FJ; Borthakur G; Ravandi F; Faderl S; Verstovsek S; Thomas D; Wierda W; Ferrajoli A; Kornblau S; Pierce S; Albitar M; Cortes J; Kantarjian H
Br J Haematol; 2007 Feb; 136(4):624-7. PubMed ID: 17223919
[TBL] [Abstract][Full Text] [Related]
18. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
Paschka P; Marcucci G; Ruppert AS; Mrózek K; Chen H; Kittles RA; Vukosavljevic T; Perrotti D; Vardiman JW; Carroll AJ; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2006 Aug; 24(24):3904-11. PubMed ID: 16921041
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
20. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel.
Stark B; Jeison M; Gabay LG; Mardoukh J; Luria D; Bar-Am I; Avrahami G; Kapeliushnik Y; Sthoeger D; Herzel G; Steinberg DM; Cohen IJ; Goshen Y; Stein J; Zaizov R; Yaniv I
Br J Haematol; 2004 Aug; 126(3):320-37. PubMed ID: 15257704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
